trametinib
trametinib is a pharmaceutical drug with 178 clinical trials. Currently 63 active trials ongoing. Historical success rate of 67.4%.
Success Metrics
Based on 60 completed trials
Phase Distribution
Phase Distribution
81
Early Stage
73
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
58.8%
60 of 102 finished
41.2%
42 ended early
63
trials recruiting
178
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Dabrafenib and/or Trametinib Rollover Study
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Clinical Trials (178)
Dabrafenib and/or Trametinib Rollover Study
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Pan Tumor Rollover Study
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
Pediatric Long-Term Follow-up and Rollover Study
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 178